NYSE:WAT - Waters Stock Price, News, & Analysis

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters declared that its board has authorized a stock repurchase program on Tuesday, April 24th 2018, which permits the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 18.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

Waters Co. (NYSE:WAT) announced its earnings results on Tuesday, October, 23rd. The medical instruments supplier reported $1.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.90 by $0.02. The medical instruments supplier earned $578.02 million during the quarter, compared to analyst estimates of $587.43 million. Waters had a net margin of 2.32% and a return on equity of 30.68%. Waters's quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.77 earnings per share. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, January 22nd 2019. View Earnings Estimates for Waters.

Waters updated its fourth quarter earnings guidance on Tuesday, October, 23rd. The company provided EPS guidance of $2.55-2.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.69. Waters also updated its FY 2018 guidance to $8.00-8.10 EPS.

16 brokerages have issued twelve-month price targets for Waters' stock. Their forecasts range from $180.00 to $230.00. On average, they anticipate Waters' share price to reach $205.3450 in the next year. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Price Targets for Waters.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 3 sell ratings, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Waters.

Media coverage about WAT stock has trended neutral this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Waters earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the next few days.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).

Waters' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc (10.19%), BlackRock Inc. (7.41%), Massachusetts Financial Services Co. MA (5.96%), Bank of New York Mellon Corp (6.00%), Baillie Gifford & Co. (3.39%) and Janus Henderson Group PLC (2.76%). Company insiders that own Waters stock include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Nomura Asset Management Co. Ltd., Massachusetts Financial Services Co. MA, Acadian Asset Management LLC, Smith Asset Management Group LP, Wells Fargo & Company MN, Renaissance Technologies LLC and Mackenzie Financial Corp. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Terrence P Kelly and Thomas P Salice. View Insider Buying and Selling for Waters.

WAT stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Bank of New York Mellon Corp, Select Equity Group L.P., Nordea Investment Management AB, Man Group plc, AQR Capital Management LLC, Commonwealth Bank of Australia and Nuance Investments LLC. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $184.29.

Waters has a market capitalization of $13.98 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

The official website for Waters is http://www.waters.com.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]